Targeting both

Inflammation and

Mitochondrial Dysfunction

for the treatment of Diseases

with high unmet need

Unlocking the Full Therapeutic Value of Natural Cell Protection Pathways

OMEICOS is focused on developing therapies that have the potential for a significant impact on cardiovascular, inflammatory and mitochondrial diseases with high unmet need. Our pipeline is based on our proprietary approach to target one of nature’s most important cell-protective pathways and industry-leading knowledge of omega-3 fatty acid metabolism and biology.

Lead compound OMT-28 has recently been tested in a double-blinded, placebo-controlled, multi-center Phase 2 clinical trial in patients suffering from atrial fibrillation. OMT-28 proved its excellent safety and tolerability profile, already shown in Phase I with 75 healthy volunteers.

In addition, the study demonstrated a significant positive effect on a number of inflammatory biomarkers, among them GDF-15 and IL-6, the strongest independent predictors of mortality and disease progression in cardiovascular diseases.

The positive effect of OMT-28 in mitochondrial dysfunction has been demonstrated. Currently, OMEICOS conducts a Phase II proof-of-concept clinical study in myopathy/cardiomyopathy in patients with primary mitochondriopathies.

The company is planning a robust clinical proof-of-concept study to confirm OMT-28’s broad anti-inflammatory effect and to leverage the validated link between reduction of CV inflammation and significant reduction of adverse events in patients with Coronary Artery Disease.

OMT-28 has shown potential for the application to other disease areas such as ophthalmology.

Latest Press Release

September 18, 2023
OMEICOS Therapeutics Provides Update on PMD-OPTION Phase 2a Clinical Study Evaluating OMT-28 in Primary Mitochondrial Disease
Read more

Upcoming Events

June 3 – 6, 2024
BIO International Convention 2024
Read more